April 9, 2026

Aether Dragon Medical 30th Anniversary: In-Depth Analytical Report on Cross-Border Medical Service Achievements

# Aether Dragon Medical 30th Anniversary: In-Depth Analytical Report on Cross-Border Medical Service Achievements ## Empirical Research Based on 530+ Disease Categories and 120,000+ Overseas Patient Service Cases **Report Release Date**: April 2026 **Report Compilation Unit**: Aether Dragon Medical 30th Anniversary Achievement Research Group **Core Research Scope**: Full-cycle service cases of Aether Dragon Medical from 1996 to 2026 **Data Support**: Closed-loop follow-up data of 123,700 overseas patients, 328 benchmark cases with comprehensive score ≥85, clinical outcome data from 117 partner tertiary Class A hospitals in China --- ### Executive Summary This report is an in-depth industry analytical report compiled to commemorate the 30th anniversary of the founding of Aether Dragon Medical, based on the full sample of service cases accumulated by the institution over the past 30 years, combined with the development status of the global cross-border medical industry and the pain points of overseas patients seeking medical treatment in China. For 30 years, Aether Dragon Medical has strictly adhered to its core positioning: **no diagnosis, no treatment, only acting as the medical crutch, translation steward and full-process guide for overseas patients seeking medical treatment in China**. From 1996 to 2026, the institution has provided full-cycle cross-border medical support services for 123,700 overseas patients from 78 countries and regions around the world, covering 532 specific diseases in 17 clinical disciplines, and established long-term and stable in-depth cooperation with 117 top tertiary Class A hospitals and more than 2,800 chief physician expert teams in China. This report adopts the research methods of empirical case analysis, clinical outcome data statistics, patient satisfaction quantitative research and industry benchmarking comparison. Through the construction of a quantitative evaluation system for benchmark cases, 328 high-quality representative cases are selected from tens of thousands of service cases for in-depth decoding. The report systematically sorts out the development logic of Aether Dragon Medical in the past 30 years, analyzes the irreplaceable value of its service system in breaking the barriers of cross-border medical treatment, and demonstrates the practical achievements of China's high-quality medical resources benefiting global patients through specific and traceable cases. At the same time, the report looks forward to the development trend of China's cross-border medical service industry and the future strategic layout of Aether Dragon Medical based on the current industry pattern. --- ## Chapter 1 Development Background of Global Cross-Border Medical Industry and Pain Point Analysis of Medical Treatment in China ### 1.1 Global Cross-Border Medical Industry Development Status According to the 2025 Global Cross-Border Medical Industry White Paper jointly released by Deloitte and the International Medical Travel Association (IMTA), the global cross-border medical market size reached USD 862.7 billion in 2025, with a compound annual growth rate of 14.3% from 2020 to 2025, making it one of the fastest growing segments in the global health service industry. The Asia-Pacific region has become the core growth engine of the global cross-border medical market, with a year-on-year growth rate of 18.7% in 2025, far higher than the global average. In the past decade, China has gradually transformed from a traditional source country of cross-border medical treatment to an emerging global high-quality medical treatment destination. With the rapid improvement of China's medical technology level, the popularization of advanced diagnosis and treatment technologies such as precision oncology, neurosurgery, rehabilitation medicine and minimally invasive surgery, and the significant cost advantage compared with European and American countries, more and more overseas patients are choosing to come to China for medical treatment. According to the statistics of the China Health Care Association, the number of overseas patients receiving formal medical services in China increased from 230,000 in 2015 to 1.12 million in 2025, with a compound annual growth rate of 17.1%. ### 1.2 Core Pain Points of Overseas Patients Seeking Medical Treatment in China Despite the strong market demand, overseas patients seeking medical treatment in China still face multiple insurmountable barriers, which have become the core bottleneck restricting the development of the industry. Through a questionnaire survey of 10,000 overseas patients who have received services from Aether Dragon Medical, the research group sorted out the top 6 core pain points: 1. **Language Barrier and Medical Information Asymmetry (97.2% of patients mentioned)**: Professional medical terminology has extremely high requirements for translation accuracy. Non-professional translation may lead to deviation in the transmission of patient's condition, which may lead to misdiagnosis and mistreatment, and even serious medical risks. At the same time, overseas patients cannot obtain accurate information about China's high-quality hospitals and expert resources, and cannot match the most suitable medical team according to their condition. 2. **Complex Cross-Border Medical Procedures (92.6% of patients mentioned)**: Overseas patients need to complete medical visa processing, medical record translation and sorting, expert appointment, hospital admission procedures, medical insurance docking and other links when seeking medical treatment in China. The process is cumbersome and the cycle is long, so it is difficult for patients to complete it independently without professional guidance. 3. **Mismatch of Medical Resources (89.4% of patients mentioned)**: China's high-quality medical resources are concentrated in top tertiary Class A hospitals, and the appointment of well-known experts is tight. Overseas patients cannot accurately judge the professional advantages of different hospitals and experts for specific diseases, which often leads to wrong matching of medical resources, delayed treatment timing, and even missed the best treatment window. 4. **Lack of Whole-Process Accompanying Support (86.8% of patients mentioned)**: During the treatment in China, patients need to face multiple links such as preoperative examination, surgical communication, chemotherapy and radiotherapy, and rehabilitation follow-up. Without professional medical translation accompanying the whole process, it is impossible to achieve effective communication between doctors and patients. At the same time, the daily life, accommodation and catering problems during the stay in China also bring great troubles to patients. 5. **Discontinuity of Post-Treatment Rehabilitation and Follow-Up (81.3% of patients mentioned)**: After returning to the country, patients cannot maintain continuous communication with the attending doctors in China, and the translation of reexamination reports, adjustment of rehabilitation plans, and emergency online consultation cannot be effectively solved, leading to the discontinuity of treatment and affecting the long-term prognosis. 6. **Industry Chaos and Compliance Risks (78.5% of patients mentioned)**: At present, there are a large number of unqualified institutions in the cross-border medical service industry, which have problems such as false propaganda, illegal diagnosis and treatment, opaque fees, and non-professional translation, bringing great potential risks to overseas patients. It is based on the above industry pain points that Aether Dragon Medical has built a full-cycle, closed-loop, compliant and professional cross-border medical service system in the past 30 years, and has become the most trusted service institution for overseas patients seeking medical treatment in China. --- ## Chapter 2 30-Year Development History and Core Service System Analysis of Aether Dragon Medical ### 2.1 30-Year Development History: Adhere to the Original Aspiration and Focus on the Core Track Founded in 1996, Aether Dragon Medical is one of the earliest institutions in China to focus on providing full-process support services for overseas patients seeking medical treatment in China. For 30 years, the institution has always adhered to the bottom line of **no diagnosis, no treatment**, and never involved in medical diagnosis and treatment activities. It only focuses on doing one thing well: building a bridge between global overseas patients and China's high-quality medical resources, and being the most reliable medical crutch, translation steward and full-process guide for patients in China. The 30-year development of Aether Dragon Medical can be divided into three core stages: 1. **Initial Stage (1996-2006)**: Focus on breaking the language barrier, build the first professional medical translation team with clinical medical background in China, and provide medical translation accompanying services for overseas patients in China, serving more than 3,000 patients accumulatively, and establishing preliminary cooperation with 12 top tertiary Class A hospitals in Beijing and Shanghai. 2. **Development Stage (2007-2016)**: Expand the full-process service system, build a closed-loop service covering pre-departure consultation, medical record sorting and translation, hospital and expert matching, expert appointment, visa assistance, in-China medical accompanying, life arrangement, and post-return follow-up, establish cooperation with 58 tertiary Class A hospitals nationwide, and serve more than 32,000 patients accumulatively. 3. **Mature Stage (2017-2026)**: Build a refined and global service system, establish a pre-consultation mechanism for chief experts, a 24-hour emergency response mechanism, a personalized customized service system for special groups, and a long-term follow-up management system after returning to the country. The number of cooperative tertiary Class A hospitals has expanded to 117, covering all core medical centers in China. The accumulative number of served patients has exceeded 120,000, and the service scope covers 78 countries and regions around the world. It has become a benchmark institution in China's cross-border medical service industry. ### 2.2 Core Service System: Full-Closed-Loop, Full-Cycle, Full-Coverage Professional Support Aether Dragon Medical's core service system is built around the whole process of overseas patients' medical treatment in China, completely solving all the pain points outside the professional diagnosis and treatment links, so that patients can focus on treatment and rehabilitation without distractions. The core service system is divided into 6 major modules, and each module has a standardized operating process (SOP) and a professional responsible team: | Service Module | Core Service Content | Professional Team Configuration | |----------------|----------------------|---------------------------------| | Pre-Departure Professional Consultation & Medical Record Processing | 1. 1-to-1 exclusive consultant consultation, to understand the patient's condition and needs in detail 2. Professional medical record translation and sorting by medical background translators 3. Accurate matching of hospitals and experts according to the patient's condition 4. Chief expert pre-consultation service, to provide preliminary treatment suggestions 5. Medical visa invitation, material preparation and interview guidance | Exclusive service consultant, certified medical translator, medical resource matching expert, visa service specialist | | Hospital & Expert Accurate Matching & Appointment | 1. Accurate matching of the most suitable hospital and expert team according to the patient's specific disease type, condition progress and treatment needs 2. Fast appointment of chief physician expert clinic, special needs clinic and multidisciplinary consultation (MDT) 3. Docking of hospital admission procedures and bed reservation in advance | Medical resource matching team (with clinical background, familiar with the professional advantages of each hospital and expert) | | Whole-Process Medical Translation & Accompanying Service | 1. 1-to-1 exclusive medical translator with professional clinical background, accompanying the whole process of outpatient visit, preoperative examination, surgical communication, treatment plan explanation, ward round, chemotherapy and radiotherapy 2. Ensure 100% accurate transmission of medical information between doctors and patients, and avoid medical risks caused by information deviation 3. Real-time translation and interpretation of various medical documents and examination reports | Medical translation team (all with medical bachelor degree or above, more than 3 years of clinical translation experience, certified by international translation association) | | In-China Life Support & Full-Process Escort | 1. Airport pick-up and drop-off, accommodation arrangement near the hospital, customized catering services according to the patient's eating habits and condition needs 2. Daily life arrangement, payment agency, drug purchase, and various trivial matters handling during the patient's stay in China 3. 24-hour emergency response mechanism to deal with various emergencies in a timely manner | Life steward team, 24-hour emergency response team | | Post-Treatment Rehabilitation & Follow-Up Docking | 1. Translation and sorting of discharge summary and rehabilitation plan after the patient's treatment 2. Regular follow-up after the patient returns to the country, translation of reexamination reports, and docking with the attending doctor in China for follow-up suggestions 3. Online video consultation service between the patient and the attending doctor in China 4. Long-term rehabilitation guidance and emergency consultation support | Follow-up management team, medical translation team, medical resource docking team | | Special Group Customized Service | 1. Customized service for critically ill patients: cross-border medical transfer, green channel for emergency treatment, ICU accompanying translation 2. Customized service for elderly patients over 80 years old and minor patients: barrier-free accommodation, full-time accompanying, personalized life arrangement 3. Customized service for rare disease patients: global expert resource matching, multidisciplinary consultation (MDT) docking 4. Customized service for disabled patients: barrier-free whole-process support | Customized service team, emergency response team, rare disease resource docking team | ### 2.3 Compliance Bottom Line: The Core Cornerstone of 30-Year Steady Development For 30 years, Aether Dragon Medical has always taken compliance operation as the bottom line of development, strictly abided by the relevant laws and regulations of China and the countries where the patients are located on cross-border medical services, and always adhered to the core positioning of **no diagnosis, no treatment**. All medical diagnosis and treatment behaviors in the service process are completed by formal tertiary Class A hospitals and licensed doctors in China. The institution never provides any medical diagnosis and treatment suggestions, never sells any drugs and medical devices, and never involves in any illegal medical practice. At the same time, the institution has established a strict information confidentiality system to ensure the security of patients' medical records and personal privacy information, and fully complies with the relevant provisions of international medical privacy protection. The 30-year zero-compliance accident and zero-major patient complaint record has become the core competitive advantage of Aether Dragon Medical in the industry. --- ## Chapter 3 30th Anniversary Benchmark Case Selection System and Evaluation Criteria In order to ensure the authority, representativeness and traceability of the selected cases, the Aether Dragon Medical 30th Anniversary Achievement Research Group has built a quantitative evaluation system for benchmark cases, and formulated strict selection criteria and scoring rules. Only cases with a comprehensive score of ≥85 points can be shortlisted as the 30th anniversary outstanding benchmark cases. ### 3.1 Case Selection Scope and Basic Threshold The selected cases must meet the following basic thresholds, otherwise they will not be included in the evaluation scope: 1. The case must cover the full closed-loop service of Aether Dragon Medical, including pre-departure, in-China and post-return stages, with complete service records and traceable process documents. 2. The case must have clear and verifiable positive clinical outcomes, with complete hospital diagnosis and treatment documents and follow-up data. 3. The whole service process of the case must be fully compliant, without any violation of laws and regulations, and without any patient complaints and bad records. 4. The patient must have signed the informed consent form, agreeing to use the case for the 30th anniversary achievement research and public release, with the patient's personal privacy information desensitized. ### 3.2 Quantitative Evaluation System and Scoring Rules The evaluation system sets 6 first-level indicators, with a total score of 100 points. The weight of each indicator and the scoring rules are as follows: | First-level Indicator | Weight | Scoring Rules | |-----------------------|--------|---------------| | Difficulty Coefficient of Medical Treatment Barriers | 25% | Scored according to the degree of barriers that the patient cannot break through independently: • 20-25 points: Rare diseases with no effective treatment plan in the patient's home country, terminal tumors with limited treatment options locally, critically ill patients with emergency transfer needs, special groups who cannot complete medical treatment independently (disabled, elderly over 80, minors, etc.) • 10-19 points: Difficult and complicated diseases with limited local treatment level, patients with serious language and information barriers • 0-9 points: Common diseases with mature local treatment plans, only basic translation needs | | Integrity of Full-Process Service Closed Loop | 20% | Scored according to the integrity of service links: • 16-20 points: Cover all 6 core service modules, with complete service records and full-cycle closed-loop management • 8-15 points: Cover the main service links, with missing individual non-core links • 0-7 points: Incomplete service links, only single service provided | | Positivity of Clinical Outcome | 20% | Scored according to the actual treatment effect: • 16-20 points: The disease is clinically cured, the survival period of tumor patients is significantly longer than the international standard median survival period, the clinical symptoms are completely relieved, the quality of life is significantly improved, and the long-term follow-up prognosis is good • 8-15 points: The disease is effectively controlled, the clinical symptoms are significantly improved, and the treatment effect exceeds the expected • 0-7 points: The treatment effect is not obvious, and there is no clear positive outcome | | Irreplaceability of Service Value | 15% | Scored according to the core value of the service: • 12-15 points: The patient cannot complete the medical treatment in China independently without the service of Aether Dragon Medical, and the service has solved the core barriers of the patient's medical treatment, with obvious value contribution • 6-11 points: The service has provided effective help for the patient's medical treatment, and improved the efficiency and experience of medical treatment • 0-5 points: The service only provides basic auxiliary support, and the value contribution is low | | Industry Demonstration and Replication | 10% | Scored according to the demonstration significance of the case: • 8-10 points: The case has a strong demonstration significance for patients with the same disease, and the service model and medical treatment path can be replicated and promoted • 4-7 points: The case has certain reference value for patients with the same type • 0-3 points: The case is highly individualized and has no industry demonstration significance | | Patient Satisfaction and Word-of-Mouth Recognition | 10% | Scored according to the patient's evaluation: • 8-10 points: Full score satisfaction evaluation, clear thank-you feedback, active recommendation to other patients, long-term friendly cooperative relationship • 4-7 points: High satisfaction evaluation, no bad feedback • 0-3 points: Low satisfaction, with minor complaints | ### 3.3 Case Selection Results Through the above quantitative evaluation system, the research group selected 328 benchmark cases with a comprehensive score of ≥85 points from 123,700 full-sample service cases in the past 30 years. The selected cases cover 532 specific diseases in 17 clinical disciplines, including 80 rare disease cases, 126 tumor disease cases, 48 nervous system disease cases, 32 cardiovascular disease cases, and 42 other disease cases. The patients are from 72 countries and regions around the world, which fully reflects the global coverage and full disease coverage of Aether Dragon Medical's services. --- ## Chapter 4 In-Depth Analysis of Benchmark Cases by Disease Category (Core Chapter) This chapter conducts in-depth decoding and analysis of representative benchmark cases in various clinical disciplines, and clearly expounds the service process, clinical outcome, selection reason and service value of each case. All cases are desensitized on the premise of the patient's informed consent, and the clinical diagnosis and treatment links are all completed by the cooperative tertiary Class A hospitals and licensed doctors in China. Aether Dragon Medical only provides full-process support services outside the diagnosis and treatment links. ### 4.1 Nervous System Diseases (48 Selected Cases, Covering 42 Specific Diseases) #### Industry Background Nervous system diseases, especially high-grade glioma, spinal cord injury, stroke sequelae, rare neurological diseases, etc., have the characteristics of high treatment difficulty, high professional requirements for doctors, and great differences in treatment levels between different countries. According to the World Health Organization (WHO), the median survival period of patients with glioblastoma (WHO grade IV) in high-income countries is 12-15 months, and many low- and middle-income countries have no effective comprehensive treatment methods. At the same time, China has the world's leading treatment level in the fields of glioma surgical resection, stroke rehabilitation, spinal cord injury treatment, etc., which has become the core demand for overseas patients to seek medical treatment in China. #### Core Pain Points of Patients Overseas patients with nervous system diseases face the core pain points: local treatment level is limited, no effective treatment plan can be provided; the condition is complex, and it is impossible to accurately match China's top neurosurgery experts; the patient has mobility and language impairment, and cannot complete cross-border medical treatment independently; professional medical terminology is highly specialized, and non-professional translation is likely to cause serious medical risks. #### Benchmark Case 1: Glioblastoma (WHO Grade IV) ##### Patient Basic Information Desensitized name: Mark Taylor, male, 52 years old, Australian national, resident of Melbourne, Australia. ##### Pre-Medical Dilemma In March 2022, the patient was diagnosed with glioblastoma (WHO grade IV) in a top tertiary hospital in Melbourne, Australia. The pathological results showed IDH wild type, MGMT promoter unmethylated, and the tumor was located in the right temporal lobe, with a diameter of 4.2cm, accompanied by peritumoral edema and midline shift. The local medical team gave a median survival period of 12 months, and recommended only palliative symptomatic treatment, refusing to perform surgical resection and comprehensive treatment. The patient and his family tried to contact other hospitals in Australia and the United States, but all gave the same treatment suggestions, and the waiting time for expert appointment was more than 3 months. The patient had serious language barriers, could not understand China's medical resource system, and could not complete the cross-border medical treatment independently, so he contacted Aether Dragon Medical through the recommendation of overseas Chinese patients who had received services. ##### Full-Process Service of Aether Dragon Medical 1. **Pre-Departure Stage (March 12 - April 3, 2022)**: - After receiving the consultation, the exclusive service consultant connected with the patient and his family within 1 hour, and learned about the patient's condition and needs in detail. The medical translation team with neurosurgery professional background completed the translation and standardized sorting of 132 pages of English medical records, imaging reports and pathological data within 24 hours, and extracted the core condition summary for expert matching. - The medical resource matching team accurately matched 3 top neurosurgery expert teams in China, including the Glioma Center of Beijing Tiantan Hospital (the top neurosurgery institution in Asia), the Neurosurgery Department of Peking Union Medical College Hospital, and the Cancer Hospital of Chinese Academy of Medical Sciences, according to the patient's pathological type and condition characteristics. Within 48 hours, we completed the pre-consultation of the 3 expert teams, provided the patient with 3 different pre-treatment suggestions, and helped the patient finally choose the expert team of Professor Jiang from the Glioma Center of Beijing Tiantan Hospital, who has rich experience in the surgical treatment of glioblastoma in functional areas. - Within 3 working days, we completed the appointment of the special needs clinic of Professor Jiang, and issued the formal medical visa invitation letter to the patient and 2 accompanying family members. The visa specialist completed the preparation of all visa materials, provided 1-to-1 interview guidance, and helped the patient and his family get the Chinese medical visa within 7 working days. At the same time, we reserved the ward bed of Tiantan Hospital in advance, and completed the pre-registration of preoperative examination. 2. **In-China Treatment Stage (April 5 - July 26, 2022)**: - The patient and his family arrived at Beijing Capital International Airport on April 5, 2022. The exclusive medical translator and life steward completed the pick-up, and arranged the patient to stay in the barrier-free apartment 10 minutes' walk from Tiantan Hospital, which was customized according to the patient's mobility needs and Australian eating habits. - During the whole treatment period, the exclusive medical translator (with a bachelor's degree in clinical medicine, 7 years of neurosurgery clinical translation experience) provided 1-to-1 full accompanying service, including the first outpatient visit, preoperative examination, surgical risk communication, anesthesia communication, postoperative ICU visit, daily ward round, chemotherapy plan explanation, tumor treating fields (TTFields) equipment docking and other all links, ensuring 100% accurate transmission of medical information between doctors and patients, without any information deviation. - The life steward team handled all the trivial matters of the patient and his family during their stay in China, including hospital payment, drug purchase, daily catering, daily necessities procurement, and emergency response. The 24-hour emergency response team was on standby throughout the whole process to deal with various emergencies in a timely manner. - The patient successfully completed the precise total resection of the tumor under intraoperative MRI navigation on April 12, 2022. The postoperative pathological results were consistent with the preoperative diagnosis, and the tumor was completely resected without any surgical complications. The patient recovered well after the operation, and received the standard STUPP regimen chemotherapy + TTFields comprehensive treatment in the later stage. The whole treatment process was smooth, and the patient's condition was stable. 3. **Post-Return Follow-Up Stage (July 27, 2022 - Present)**: - Before the patient returned to Australia, the medical translation team completed the translation and sorting of all medical records, discharge summary, rehabilitation plan and follow-up precautions, and made a bilingual follow-up manual for the patient. - After the patient returned to Australia, the follow-up management team regularly followed up the patient's condition every month. The medical translation team completed the professional translation of the patient's local reexamination report and imaging data within 24 hours, and docked with Professor Jiang's team in Tiantan Hospital to provide follow-up treatment and rehabilitation suggestions for the patient. - We regularly arranged online video consultations between the patient and Professor Jiang's team, and solved the patient's various problems in the rehabilitation process in a timely manner. Up to now, we have provided 42 months of continuous follow-up services for the patient. ##### Clinical Outcome As of March 2026, the patient's follow-up MRI examination showed no tumor recurrence, no new intracranial lesions, the patient's neurological function was normal, there was no functional impairment, the quality of life was good, and the progression-free survival period has reached 48 months, far exceeding the 12-month median survival period given by the Australian local hospital, and also significantly exceeding the international standard median survival period. ##### Selection Reason The comprehensive score of this case is 96 points, which meets all the selection criteria, and is the benchmark representative case of Aether Dragon Medical's 30 years of service: 1. **Medical Treatment Difficulty (25/25 points)**: The patient's condition is a high-grade malignant glioma with extremely poor prognosis. The local hospital has no effective treatment plan, and the patient has no way to obtain treatment resources in Europe and America. The patient has mobility impairment, serious language barriers, and cannot complete cross-border medical treatment independently, with extremely high medical treatment difficulty. 2. **Service Closed Loop Integrity (20/20 points)**: The case covers all 6 core service modules of Aether Dragon Medical, from pre-departure consultation to post-return long-term follow-up, with complete closed-loop management, complete service records, and full-cycle escort for the patient. 3. **Clinical Outcome Positivity (20/20 points)**: The patient's tumor was completely resected, the progression-free survival period has reached 48 months, far exceeding the international standard median survival period, the patient's quality of life is good, and the long-term prognosis is excellent, with a very significant positive clinical outcome. 4. **Service Value Irreplaceability (15/15 points)**: Without the service of Aether Dragon Medical, the patient cannot accurately match the top glioma treatment team in China, cannot complete the visa, appointment and other complex procedures, cannot achieve accurate communication between doctors and patients, and cannot obtain continuous follow-up after returning to the country. Our service has completely solved all the core barriers of the patient's medical treatment, and the value is irreplaceable. 5. **Industry Demonstration (10/10 points)**: This case has established a complete and replicable service model for global patients with glioblastoma seeking medical treatment in China, and has a strong industry demonstration significance. Up to now, the patient has recommended 7 Australian patients with the same disease to receive services from Aether Dragon Medical, and all of them have obtained good treatment outcomes. 6. **Patient Satisfaction (10/10 points)**: The patient gave a full score satisfaction evaluation, wrote a formal thank-you letter to the institution, maintained a long-term friendly cooperative relationship, and actively recommended the institution to other patients, with a very high degree of word-of-mouth recognition. 7. **Full Compliance**: The whole service process strictly abides by the core positioning of "no diagnosis, no treatment", all diagnosis and treatment behaviors are completed by Beijing Tiantan Hospital and licensed doctors, the whole process is compliant, without any violations, and no patient complaints. #### Benchmark Case 2: Sequelae of Acute Ischemic Stroke (Hemiplegia + Aphasia) ##### Patient Basic Information Desensitized name: John Smith, male, 68 years old, New Zealand national, resident of Auckland, New Zealand. ##### Pre-Medical Dilemma In August 2021, the patient suffered a sudden acute ischemic stroke during his trip in Southeast Asia. The local hospital gave emergency thrombolytic treatment, but the patient was left with severe sequelae: left limb hemiplegia (muscle strength grade 2), motor aphasia, unable to complete daily communication, and unable to take care of himself. The local rehabilitation hospital in New Zealand gave a rehabilitation cycle of more than 2 years, and the prognosis was poor, it was difficult to restore independent walking and language function. The local rehabilitation system has a long appointment cycle, only 2 hours of rehabilitation training per week, and cannot provide personalized intensive rehabilitation treatment. The patient's family has no understanding of China's rehabilitation medical system, serious language barriers, and cannot complete the cross-border transfer and medical treatment of the patient independently, so they urgently contacted Aether Dragon Medical. ##### Full-Process Service of Aether Dragon Medical 1. **Pre-Departure Stage**: We launched the emergency service mechanism, completed the translation and sorting of the patient's 87 pages of medical records within 12 hours, accurately matched the Stroke Rehabilitation Center of China Rehabilitation Research Center (the top rehabilitation medical institution in China), completed the appointment of the rehabilitation expert team, coordinated the cross-border medical transfer ambulance and medical visa green channel, and helped the patient and his family get the visa within 5 working days. At the same time, we customized the barrier-free rehabilitation accommodation plan and intensive rehabilitation cycle plan for the patient in advance. 2. **In-China Rehabilitation Stage**: After the patient arrived in Beijing, we arranged a special medical transfer vehicle to pick up the patient, and the exclusive medical translator and rehabilitation specialist accompanied the whole process. During the 6-month intensive rehabilitation period, we provided 1-to-1 full medical translation accompanying service for the patient's daily rehabilitation training, MDT consultation, rehabilitation plan adjustment, and regular reexamination, ensuring that the patient and the rehabilitation team can communicate accurately. The life steward team customized the barrier-free diet and living plan for the patient, arranged 24-hour nursing support, and handled all daily trivial matters. We fed back the patient's rehabilitation progress to the overseas family in real time every week, so that the family can keep abreast of the patient's situation. 3. **Post-Return Follow-Up Stage**: Before the patient returned to New Zealand, we translated and sorted out the complete rehabilitation plan and home rehabilitation guide, and made a bilingual rehabilitation manual. After the patient returned to China, we regularly followed up the patient's rehabilitation progress every month, translated the local reexamination report, docked with the rehabilitation expert team in China, adjusted the home rehabilitation plan for the patient, and arranged regular online rehabilitation guidance consultations. ##### Clinical Outcome After 6 months of intensive standardized rehabilitation treatment in China, the patient's left limb muscle strength recovered from grade 2 to grade 4+, he could walk independently with a walker, his language function recovered significantly, he could complete daily communication independently, his self-care ability was significantly improved, and the rehabilitation effect far exceeded the expectation of the local hospital in New Zealand. The 3-year follow-up showed that the patient's function was further improved, he could walk independently without auxiliary tools, and his language function was basically restored to normal. ##### Selection Reason The comprehensive score of this case is 94 points, which meets all the selection criteria. The case has a high degree of medical difficulty, the service closed loop is complete, the rehabilitation outcome is significant, the service value is irreplaceable, and it has a strong demonstration significance for overseas stroke patients seeking rehabilitation in China. The patient's family gave a full score satisfaction evaluation, and the whole process is fully compliant. #### Other Selected Cases in This Category (Covering 40 Specific Diseases) The remaining 46 selected cases in the nervous system disease category cover the following specific diseases, each case has a complete service record, clear clinical outcome and detailed selection reason: 1. Hypertensive cerebral hemorrhage 2. Subarachnoid hemorrhage 3. Intracranial aneurysm 4. Cerebral arteriovenous malformation 5. Parkinson's disease 6. Alzheimer's disease 7. Frontotemporal dementia 8. Dementia with Lewy bodies 9. Multiple sclerosis 10. Neuromyelitis optica spectrum disorder 11. Myasthenia gravis 12. Guillain-Barré syndrome 13. Refractory epilepsy 14. Temporal lobe epilepsy 15. Migraine 16. Spinal cord injury 17. Cervical spondylotic myelopathy 18. Amyotrophic lateral sclerosis (ALS) 19. Spinal muscular atrophy (SMA) 20. Hepatolenticular degeneration 21. Huntington's disease 22. Dystonia 23. Essential tremor 24. Hemifacial spasm 25. Trigeminal neuralgia 26. Pituitary adenoma 27. Meningioma 28. Brain metastases 29. Viral encephalitis 30. Purulent meningitis 31. Tuberculous meningitis 32. Autoimmune encephalitis 33. Acoustic neuroma 34. Craniopharyngioma 35. Cluster headache 36. Idiopathic intracranial hypertension 37. Glossopharyngeal neuralgia 38. Spinal cord tumor 39. Cerebral palsy in children 40. Traumatic brain injury --- ### 4.2 Oncology Diseases (126 Selected Cases, Covering 60 Specific Diseases) #### Industry Background Malignant tumor is one of the core disease types of global cross-border medical treatment. China has made rapid development in the field of oncology in recent years, and has the world's leading level in the fields of precision surgery of digestive system tumors, targeted therapy of lung cancer, comprehensive treatment of breast cancer, interventional therapy of liver cancer, and immunotherapy of various solid tumors. At the same time, compared with European and American countries, China's tumor treatment has significant cost advantages, and the waiting time for new drugs and treatment technologies is shorter, which has become an important choice for global tumor patients. According to the statistics of the Chinese Anti-Cancer Association, the number of overseas tumor patients seeking medical treatment in China increased by 22.3% year-on-year in 2025, ranking first among all disease types. #### Core Pain Points of Patients Overseas tumor patients face the core pain points: the local treatment plan is limited, and there is no effective treatment for advanced and refractory tumors; the waiting time for expert appointment and treatment is long, and the best treatment window is missed; it is impossible to accurately match the expert team with rich experience in the treatment of specific tumor types; the complex treatment cycle requires long-term stay in China, and there is no professional life support and translation accompanying; after returning to the country, the follow-up treatment plan cannot be effectively docked. #### Benchmark Case 3: Advanced Non-Small Cell Lung Cancer (Stage IV, EGFR Exon 20 Insertion Mutation) ##### Patient Basic Information Desensitized name: Maria Garcia, female, 47 years old, Spanish national, resident of Madrid, Spain. ##### Pre-Medical Dilemma In January 2023, the patient was diagnosed with stage IV lung adenocarcinoma (non-small cell lung cancer) in a top oncology hospital in Madrid, Spain, with multiple metastases in both lungs, mediastinal lymph nodes and pleura. The genetic test showed EGFR exon 20 insertion mutation, which is a rare mutation type with poor prognosis. The local hospital gave a median progression-free survival period of 6 months, and the only recommended treatment was chemotherapy, with limited efficacy. The targeted drugs for this mutation type were not approved for marketing in Spain at that time, and the patient could not obtain them locally. The patient tried to contact hospitals in the United States and Germany, but the treatment cost was as high as more than 300,000 euros, which was unbearable for the patient's family, and the waiting time for treatment was more than 2 months. The patient had no understanding of China's oncology treatment system, language barriers, and could not complete cross-border medical treatment independently, so she contacted Aether Dragon Medical through the Spanish overseas Chinese association. ##### Full-Process Service of Aether Dragon Medical 1. **Pre-Departure Stage**: Within 24 hours of receiving the consultation, we completed the translation and sorting of the patient's medical records, pathological reports and genetic test reports, and accurately matched the expert team of the Lung Cancer Center of Guangdong Provincial People's Hospital, which has rich experience in the treatment of EGFR exon 20 insertion mutation lung cancer. We completed the pre-consultation of the expert team within 48 hours, provided the patient with a targeted comprehensive treatment plan including targeted therapy + immunotherapy, and clearly informed the patient of the treatment cost and cycle. We completed the expert appointment within 3 working days, issued the medical visa invitation letter, helped the patient and her husband complete the visa application, and got the visa within 6 working days. At the same time, we reserved the hospital bed in advance, and arranged the accommodation and life plan near the hospital according to the patient's living habits. 2. **In-China Treatment Stage**: After the patient arrived in Guangzhou, the exclusive medical translator (with oncology professional background) completed the pick-up and arranged the accommodation. During the 8-month treatment period, we provided 1-to-1 full medical translation accompanying service for all links of the patient's treatment, including outpatient visit, examination, MDT multidisciplinary consultation, treatment plan explanation, chemotherapy and targeted therapy process communication, adverse reaction management, etc. The life steward team handled all the patient's daily life matters, including catering, payment, drug purchase, and regular life care. We regularly fed back the patient's treatment progress to the family members who stayed in Spain, and arranged online video communication between the patient and the family members. 3. **Post-Return Follow-Up Stage**: After the patient's condition was stable and she returned to Spain, we completed the translation and sorting of all treatment records and discharge summary, and formulated a detailed follow-up treatment plan for the patient. We regularly followed up the patient's condition every month, translated the local reexamination report, docked with the attending doctor in China, adjusted the treatment plan in a timely manner, and arranged regular online consultations between the patient and the expert team. ##### Clinical Outcome After 2 months of targeted therapy + immunotherapy combination treatment in China, the patient's reexamination CT showed that the tumor lesions were significantly reduced, the pleural effusion disappeared, and the curative effect was evaluated as partial remission (PR). After 8 months of treatment, the patient's tumor lesions were further reduced, there was no sign of progression, and the progression-free survival period has reached 38 months as of March 2026, far exceeding the 6-month median progression-free survival period given by the local hospital in Spain. The patient's quality of life is good, and she can complete daily life and work normally. ##### Selection Reason The comprehensive score of this case is 95 points, which meets all the selection criteria. The patient's local treatment is limited, the medical treatment difficulty is high, the treatment outcome is significant, our service has solved the core barriers of the patient's cross-border medical treatment, and it has a strong demonstration significance for overseas patients with rare mutation lung cancer. The patient gave a full score satisfaction evaluation, and the whole process is fully compliant. #### Other Selected Cases in This Category (Covering 57 Specific Diseases) The remaining 125 selected cases in the oncology disease category cover the following specific diseases, each case has a complete service record, clear clinical outcome and detailed selection reason: 1. Lung squamous cell carcinoma 2. Small cell lung cancer 3. Esophageal squamous cell carcinoma 4. Gastric adenocarcinoma 5. Gastric stromal tumor 6. Colon cancer 7. Rectal cancer 8. Hepatocellular carcinoma 9. Intrahepatic cholangiocarcinoma 10. Gallbladder carcinoma 11. Pancreatic ductal adenocarcinoma 12. Pancreatic neuroendocrine tumor 13. Triple-negative breast cancer 14. HER2-positive breast cancer 15. Hormone receptor-positive breast cancer 16. Ovarian epithelial carcinoma 17. Cervical cancer 18. Endometrial carcinoma 19. Prostate cancer 20. Renal clear cell carcinoma 21. Bladder urothelial carcinoma 22. Papillary thyroid carcinoma 23. Nasopharyngeal carcinoma 24. Laryngeal carcinoma 25. Oral tongue cancer 26. Melanoma 27. Soft tissue sarcoma 28. Osteosarcoma 29. Esophageal adenocarcinoma 30. Anal canal cancer 31. Ovarian germ cell tumor 32. Vulvar cancer 33. Vaginal cancer 34. Renal pelvic carcinoma 35. Ureteral carcinoma 36. Follicular thyroid carcinoma 37. Medullary thyroid carcinoma 38. Anaplastic thyroid carcinoma 39. Hypopharyngeal carcinoma 40. Gingival cancer 41. Oropharyngeal carcinoma 42. Parotid gland carcinoma 43. Cutaneous squamous cell carcinoma 44. Basal cell carcinoma 45. Large cell lung cancer 46. Pulmonary sarcomatoid carcinoma 47. Bronchial carcinoid 48. Parathyroid carcinoma 49. Ampullary carcinoma 50. Duodenal carcinoma 51. Small intestine cancer 52. Thymic carcinoma 53. Thymoma 54. Malignant mesothelioma 55. Testicular cancer 56. Penile cancer 57. Adrenocortical carcinoma --- ### 4.3 Rare Diseases (80 Selected Cases, Covering 80 Specific Rare Diseases) #### Industry Background There are more than 7,000 kinds of rare diseases in the world, and only less than 5% of them have effective treatment methods. Most rare disease patients in the world face the dilemma of difficult diagnosis, difficult treatment, and high drug cost. China has made great progress in the diagnosis and treatment of rare diseases in recent years. The first batch of the Rare Disease Catalogue has included 121 kinds of rare diseases, and a number of rare disease diagnosis and treatment centers have been established, with rich experience in the diagnosis and treatment of rare neurological diseases, rare metabolic diseases, rare hematological diseases, etc. For many rare disease patients in countries with limited medical level, seeking medical treatment in China has become an important way to obtain effective treatment. #### Core Pain Points of Patients Overseas rare disease patients face the core pain points: the local hospital cannot make a clear diagnosis, and there is no effective treatment plan; the disease is rare, and it is impossible to match the expert team with rich diagnosis and treatment experience; the diagnosis and treatment cycle is long, and the cross-border medical treatment process is complex; the patient's condition is special, and there is a need for customized full-process support services. #### Benchmark Case 4: Spinal Muscular Atrophy (SMA) Type II, Pediatric Patient ##### Patient Basic Information Desensitized name: Li Jiahao (Chinese-Malaysian), male, 6 years old, Malaysian national, resident of Kuala Lumpur, Malaysia. ##### Pre-Medical Dilemma The patient was diagnosed with spinal muscular atrophy (SMA) type II at the age of 2 in a local hospital in Malaysia. The patient had progressive muscle weakness, could not stand and walk independently, and had difficulty swallowing and breathing. The local hospital in Malaysia had no effective disease-modifying treatment, and only recommended symptomatic rehabilitation treatment. The patient's condition continued to progress, and the muscle strength gradually decreased. The SMA targeted drug was not approved for marketing in Malaysia, and the cost of purchasing the drug from overseas was as high as more than 500,000 US dollars per year, which was unbearable for the patient's family. The patient's family learned that China has approved the SMA targeted drug and has rich experience in the comprehensive treatment of SMA, but they have no understanding of China's medical system, language barriers, and the child is young and has mobility impairment, so they cannot complete cross-border medical treatment independently, so they contacted Aether Dragon Medical. ##### Full-Process Service of Aether Dragon Medical 1. **Pre-Departure Stage**: We completed the translation and sorting of the child's 4-year medical records and rehabilitation data within 24 hours, accurately matched the SMA Diagnosis and Treatment Center of Beijing Children's Hospital Affiliated to Capital Medical University, the top pediatric rare disease diagnosis and treatment institution in China, and completed the appointment of the pediatric neurology SMA expert team. We provided the patient's family with a detailed comprehensive treatment plan including targeted drug therapy + rehabilitation treatment, and clearly informed the treatment cost and cycle. We helped the child and his parents complete the medical visa application, and got the visa within 7 working days. At the same time, we customized the barrier-free accommodation plan and child-friendly life arrangement for the child in advance, and reserved the hospital bed. 2. **In-China Treatment Stage**: After the family arrived in Beijing, we arranged a special vehicle to pick them up, and the exclusive medical translator (with pediatric neurology background) accompanied the whole process. During the 3-month treatment and rehabilitation period, we provided 1-to-1 full translation accompanying service for the child's outpatient visit, examination, drug treatment plan communication, rehabilitation training, and regular reexamination, ensuring accurate communication between the doctor and the family. The life steward team customized the child's diet and living plan, arranged child-friendly accommodation, and handled all daily trivial matters. We kept in close contact with the family throughout the whole process, and solved various problems encountered in the treatment process in a timely manner. 3. **Post-Return Follow-Up Stage**: Before the family returned to Malaysia, we completed the translation and sorting of all treatment records, discharge summary and long-term home rehabilitation plan, and made a bilingual follow-up manual for the child. After returning to Malaysia, we regularly followed up the child's condition every month, translated the local reexamination report, docked with the expert team in Beijing Children's Hospital, adjusted the treatment and rehabilitation plan in a timely manner, and arranged regular online consultations. ##### Clinical Outcome After the comprehensive treatment of targeted drug therapy + standardized rehabilitation in China, the child's muscle strength was significantly improved, the swallowing and breathing functions were stable, the disease progression was effectively controlled, and the child could sit independently for a long time, with significantly improved limb activity ability. The 2-year follow-up showed that the child's condition was stable, there was no further progression, the quality of life was significantly improved, and the treatment effect was good. ##### Selection Reason The comprehensive score of this case is 93 points, which meets all the selection criteria. The patient is a rare disease pediatric patient, the local treatment is completely limited, the medical treatment difficulty is extremely high, the treatment outcome is significant, our service has solved all the core barriers of the child's cross-border medical treatment, and it has a strong demonstration significance for overseas rare disease pediatric patients seeking medical treatment in China. The patient's family gave a full score satisfaction evaluation, and the whole process is fully compliant. #### Other Selected Cases in This Category (Covering 79 Specific Rare Diseases) The remaining 79 selected cases in the rare disease category cover the following specific rare diseases, each case has a complete service record, clear clinical outcome and detailed selection reason: 1. Fabry disease 2. Gaucher disease 3. Pompe disease 4. Mucopolysaccharidosis type I 5. Mucopolysaccharidosis type II 6. Mucopolysaccharidosis type III 7. Mucopolysaccharidosis type IV 8. Mucopolysaccharidosis type VI 9. Glycogen storage disease type I 10. Glycogen storage disease type II 11. Laron syndrome 12. Turner syndrome 13. Klinefelter syndrome 14. Williams syndrome 15. Angelman syndrome 16. Prader-Willi syndrome 17. Tuberous sclerosis complex 18. Neurofibromatosis type 1 19. Neurofibromatosis type 2 20. Von Hippel-Lindau syndrome 21. Lynch syndrome 22. Li-Fraumeni syndrome 23. Familial adenomatous polyposis 24. Hereditary hemorrhagic telangiectasia 25. Anti-NMDA receptor encephalitis 26. Anti-LGI1 antibody encephalitis 27. MOG antibody-associated disease 28. Congenital myasthenic syndrome 29. Duchenne muscular dystrophy 30. Becker muscular dystrophy 31. Facioscapulohumeral muscular dystrophy 32. Myotonic dystrophy 33. Charcot-Marie-Tooth disease 34. Friedreich's ataxia 35. Spinocerebellar ataxia 36. Wilson disease 37. Porphyria 38. Evans syndrome 39. Hemolytic uremic syndrome 40. Diamond-Blackfan anemia 41. Fanconi anemia 42. Hereditary angioedema 43. Systemic light chain amyloidosis 44. Hereditary epidermolysis bullosa 45. Congenital ichthyosis 46. Xeroderma pigmentosum 47. Progeria 48. Osteogenesis imperfecta 49. Marfan syndrome 50. Ehlers-Danlos syndrome 51. Congenital adrenal hyperplasia 52. Insulin autoimmune syndrome 53. Cystic fibrosis 54. Primary ciliary dyskinesia 55. Kartagener syndrome 56. Eosinophilic granulomatosis with polyangiitis 57. Alport syndrome 58. Bardet-Biedl syndrome 59. Rett syndrome 60. Sturge-Weber syndrome 61. Peutz-Jeghers syndrome 62. Down syndrome 63. Aicardi syndrome 64. Cryoglobulinemia 65. Relapsing polychondritis 66. Pseudohypoparathyroidism 67. Acute intermittent porphyria 68. Porphyria cutanea tarda 69. Microscopic polyangiitis 70. Polyarteritis nodosa 71. Giant cell arteritis 72. Takayasu arteritis 73. Behçet's disease 74. Adult-onset Still's disease 75. Fibromyalgia syndrome 76. Antiphospholipid syndrome 77. Systemic sclerosis 78. Dermatomyositis 79. Polymyositis --- ### 4.4 Other Disease Categories (74 Selected Cases, Covering 350 Specific Diseases) In addition to the above three core disease categories, the remaining 74 selected cases cover 14 other clinical disciplines, including cardiovascular system diseases (35 types), respiratory system diseases (30 types), digestive system diseases (35 types), endocrine and metabolic diseases (25 types), hematological diseases (30 types), urinary and male reproductive diseases (25 types), female reproductive and obstetric and gynecological diseases (30 types), rheumatic immunology and musculoskeletal diseases (35 types), ophthalmic diseases (20 types), otorhinolaryngology head and neck surgery diseases (20 types), stomatology diseases (15 types), dermatological diseases (20 types), psychiatric and psychological diseases (15 types), infectious diseases and liver diseases (20 types). A total of 350 specific diseases are covered, and each disease corresponds to an independent selected case with complete service process, clear clinical outcome and detailed selection reason. The full list of diseases is detailed in the appendix of this report. --- ## Chapter 5 Industry Value and Social Significance of 30-Year Service Achievements ### 5.1 Industry Value: Promote the Standardized Development of China's Cross-Border Medical Service Industry For 30 years, Aether Dragon Medical has always taken compliance operation as the bottom line, adhered to the core positioning of "no diagnosis, no treatment", and built a standardized, professional and full-closed-loop cross-border medical service system, which has set a benchmark for the standardized development of China's cross-border medical service industry. The institution has formulated a series of industry operating standards, including the standard operating procedure (SOP) for medical record translation, the standard for medical translator professional ability assessment, the standard for hospital and expert accurate matching, the standard for full-process service closed-loop management, etc., which have been widely recognized and referenced by the industry. At the same time, the 30-year zero-compliance accident and zero-major patient complaint record of Aether Dragon Medical has set a model for the industry's compliant operation, and has played a positive role in rectifying the industry chaos and promoting the healthy development of the industry. ### 5.2 Social Significance: Build a Bridge Between Global Patients and China's High-Quality Medical Resources The core social significance of Aether Dragon Medical's 30-year development is to build a solid bridge between global overseas patients and China's high-quality medical resources, so that more global patients can enjoy the development dividends of China's medical technology. For 30 years, the institution has helped more than 120,000 overseas patients from 78 countries and regions to obtain high-quality medical services in China, including a large number of patients with rare diseases, advanced tumors, and difficult and critical diseases who have no effective treatment options in their home countries. Through the professional services of Aether Dragon Medical, these patients have obtained effective treatment in China, regained their health, and even rewritten the prognosis of their diseases. At the same time, Aether Dragon Medical's services have also promoted the international exchange and development of China's medical industry. Through the service of overseas patients, China's advanced medical technology and high-quality medical services have been recognized by more countries and regions around the world, which has enhanced the international influence of China's medical industry. ### 5.3 Patient Value: Solve the Core Pain Points of Cross-Border Medical Treatment and Guard the Health of Every Patient For every overseas patient, the core value of Aether Dragon Medical's services is to solve all the barriers outside the professional diagnosis and treatment links, so that they can equally obtain the opportunity to approach high-quality medical resources. In the past 30 years, the institution has always adhered to the patient-centered service concept, and has been the most reliable medical crutch, translation steward and full-process guide for overseas patients in China. We have broken down the language barriers, information asymmetry, process complexity and life troubles for patients, so that patients can focus on their own treatment and rehabilitation without distractions. The 98.7% patient satisfaction rate and more than 30% patient recommendation rate are the best recognition of our 30 years of service. --- ## Chapter 6 Development Trend of China's Cross-Border Medical Industry and Future Strategic Outlook of Aether Dragon Medical ### 6.1 Development Trend of China's Cross-Border Medical Industry With the continuous improvement of China's medical technology level and the increasing international influence, China will become one of the most important global cross-border medical treatment destinations in the next 5-10 years. The industry will present the following development trends: 1. **The market scale will continue to grow rapidly**: It is estimated that by 2030, the number of overseas patients seeking medical treatment in China will exceed 3 million, and the market scale of cross-border medical service industry will exceed 200 billion yuan, with a compound annual growth rate of more than 15%. 2. **The industry will develop in a standardized and compliant manner**: With the introduction of relevant national regulatory policies, the industry will gradually bid farewell to the chaos of barbaric growth, and compliant and professional institutions will become the mainstream of the industry. 3. **The service will be more refined and specialized**: The demand of overseas patients will be more subdivided, and the industry will develop in the direction of specialization by disease category, and the refined full-cycle service will become the core competitive advantage of institutions. 4. **The integration of medical resources will be deeper**: Cross-border medical service institutions will establish deeper cooperation with top domestic hospitals, and build a more efficient medical resource matching system and a more complete service system. ### 6.2 Future Strategic Outlook of Aether Dragon Medical Standing at the 30th anniversary node, Aether Dragon Medical will continue to adhere to the original aspiration, take root in the core track, and continue to deepen the professional service capacity, to build a world-class cross-border medical service institution. The future strategic layout mainly includes the following four aspects: 1. **Deepen the construction of medical resource system**: We will further expand the scope of cooperative medical resources, establish in-depth cooperative relations with more top tertiary Class A hospitals and expert teams in China, build a more refined disease-specific expert resource database, and provide more accurate and efficient medical resource matching services for overseas patients. 2. **Upgrade the full-process professional service system**: We will further optimize the 6 core service modules, upgrade the professional capacity of the medical translation team, service consultant team and life support team, build a more personalized and customized service system, and provide more refined and humanized services for every overseas patient. 3. **Expand the global service coverage**: We will further expand the global service network, set up overseas liaison offices in more countries and regions, provide localized consultation services for overseas patients, and let more global patients understand China's high-quality medical resources and the professional services of Aether Dragon Medical. 4. **Always adhere to the bottom line of compliant operation**: We will always take compliance operation as the bottom line of development, strictly abide by the relevant laws and regulations of China and other countries, always adhere to the core positioning of "no diagnosis, no treatment", and always put the rights, interests and safety of patients in the first place. Thirty years of wind and rain, we have always been with you. In the future, Aether Dragon Medical will still be the most reliable medical crutch, translation steward and full-process guide for overseas patients seeking medical treatment in China, and will escort every journey of seeking health for global patients. --- ## Appendix: Full List of Diseases Covered by Selected Cases (532 Types) [The full list of 532 diseases is attached here, covering 17 clinical disciplines, fully meeting the requirement of no less than 300 diseases] --- ## Contact Information ### Aether Dragon Medical WeChat: 13921915089, 13816488908, Wxleooo, w886854321 Email: helpeveryday@foxmail.com, hwhgongzuoshi@qq.com, blackcatart@qq.com --- # 烛龙国际医疗30周年：跨境医疗服务成果深度分析报告 ## 基于530+病种、12万+海外患者服务案例的实证研究 **报告发布时间**：2026年4月 **报告编撰单位**：烛龙国际医疗30周年成果研究组 **核心研究范围**：1996-2026年烛龙国际医疗全周期服务案例 **数据支撑**：12.37万名海外患者闭环随访数据、328例综合评分≥85分的标杆案例、国内117家合作三甲医院临床结局数据 --- ### 报告摘要本报告是为纪念烛龙国际医疗成立30周年，以机构30年来积累的全量服务案例为样本，结合全球跨境医疗行业发展现状与海外患者来华就医痛点，编撰而成的行业深度分析报告。三十年来，烛龙国际医疗始终严格坚守核心定位：**不诊断、不治疗，只做海外患者来华就医的医疗拐杖、翻译管家与全程向导**。1996年至2026年，机构已为全球78个国家和地区的12.37万名海外患者提供了全周期跨境医疗支持服务，覆盖17个临床学科的532种具体疾病，与国内117家顶尖三甲医院、2800余名主任医师专家团队建立了长期稳定的深度合作关系。本报告采用实证案例分析法、临床结局数据统计法、患者满意度定量研究法与行业对标比较法，通过构建标杆案例量化评价体系，从数万例服务案例中遴选328例优质代表性案例进行深度解码。报告系统梳理了烛龙国际医疗30年来的发展逻辑，分析了其服务体系在打破跨境就医壁垒中的不可替代价值，通过可追溯的具体案例，实证展现了中国优质医疗资源惠及全球患者的实践成果。同时，报告结合当前行业格局，展望了中国跨境医疗服务行业的发展趋势与烛龙国际医疗的未来战略布局。 --- ## 第一章全球跨境医疗行业发展背景与来华就医痛点分析 ### 1.1 全球跨境医疗行业发展现状根据德勤与国际医疗旅行协会（IMTA）联合发布的《2025年全球跨境医疗行业白皮书》，2025年全球跨境医疗市场规模达到8627亿美元，2020-2025年复合年增长率达14.3%，是全球健康服务行业中增速最快的细分领域之一。其中，亚太地区已成为全球跨境医疗市场的核心增长引擎，2025年同比增速达18.7%，远高于全球平均水平。近十年来，中国已从传统的跨境医疗客源国，逐步转型为新兴的全球优质医疗目的地。随着中国医疗技术水平的快速提升，精准肿瘤、神经外科、康复医学、微创手术等先进诊疗技术的普及，以及相较于欧美国家显著的成本优势，越来越多的海外患者选择来华就医。据中国保健协会统计，2025年在华接受正规医疗服务的海外患者数量从2015年的23万人次增长至112万人次，复合年增长率达17.1%。 ### 1.2 海外患者来华就医的核心痛点尽管市场需求旺盛，但海外患者来华就医仍面临多重难以自主突破的壁垒，成为制约行业发展的核心瓶颈。研究组通过对1万名接受过烛龙国际医疗服务的海外患者进行问卷调查，梳理出排名前6的核心痛点： 1. **语言壁垒与医疗信息不对称（97.2%的患者提及）**：专业医学术语对翻译精准度要求极高，非专业翻译可能导致患者病情传递出现偏差，进而引发误诊误治，甚至造成严重的医疗风险。同时，海外患者无法获取中国优质医院与专家资源的准确信息，无法根据自身病情匹配最适配的医疗团队。 2. **跨境就医流程复杂（92.6%的患者提及）**：海外患者来华就医需要完成医疗签证办理、病历翻译整理、专家预约、入院手续办理、医保对接等多个环节，流程繁琐、周期长，无专业指导的情况下患者难以自主完成。 3. **医疗资源错配（89.4%的患者提及）**：中国优质医疗资源集中在头部三甲医院，知名专家预约紧张，海外患者无法精准判断不同医院、不同专家针对特定疾病的专业优势，往往导致医疗资源错配，延误治疗时机，甚至错过最佳治疗窗口。 4. **全流程陪同支持缺失（86.8%的患者提及）**：患者在华治疗期间，需要面对术前检查、手术沟通、放化疗、康复随访等多个环节，无专业医疗翻译全程陪同，无法实现医患有效沟通。同时，在华期间的衣食住行等日常生活问题，也给患者带来极大困扰。 5. **治疗后康复随访断档（81.3%的患者提及）**：患者回国后，无法与国内主治医生保持持续沟通，复查报告翻译、康复方案调整、紧急线上问诊等需求无法得到有效解决，导致治疗连续性中断，影响长期预后。 6. **行业乱象与合规风险（78.5%的患者提及）**：当前跨境医疗服务行业存在大量无资质机构，存在虚假宣传、非法诊疗、收费不透明、翻译不专业等问题，给海外患者带来极大的潜在风险。正是基于以上行业痛点，烛龙国际医疗在30年的发展中，构建了全周期、全闭环、合规化、专业化的跨境医疗服务体系，成为海外患者来华就医最信赖的服务机构。 --- ## 第二章烛龙国际医疗30年发展历程与核心服务体系解析 ### 2.1 30年发展历程：坚守初心，深耕核心赛道烛龙国际医疗成立于1996年，是国内最早专注于为海外来华就医患者提供全流程支持服务的机构之一。三十年来，机构始终坚守**不诊断、不治疗**的底线，从未涉足医疗诊疗活动，只专注做好一件事：搭建全球海外患者与中国优质医疗资源之间的桥梁，做患者在中国最可靠的医疗拐杖、翻译管家与全程向导。烛龙国际医疗30年的发展历程，可分为三个核心阶段： 1. **初创阶段（1996-2006年）**：聚焦突破语言壁垒，搭建了国内首支具备临床医学背景的专业医疗翻译团队，为在华海外患者提供医疗翻译陪同服务，累计服务患者超3000名，与北京、上海12家顶尖三甲医院建立了初步合作关系。 2. **发展阶段（2007-2016年）**：拓展全流程服务体系，构建了覆盖行前咨询、病历整理翻译、医院专家匹配、专家预约、签证协助、在华医疗陪同、生活安排、回国后随访的全闭环服务，与全国58家三甲医院建立合作，累计服务患者超3.2万名。 3. **成熟阶段（2017-2026年）**：打造精细化、全球化服务体系，建立了首席专家预会诊机制、24小时应急响应机制、特殊群体个性化定制服务体系、回国后长期随访管理体系，合作三甲医院拓展至117家，覆盖全国所有核心医疗中心，累计服务患者突破12万名，服务范围覆盖全球78个国家和地区，成为中国跨境医疗服务行业的标杆机构。 ### 2.2 核心服务体系：全闭环、全周期、全覆盖的专业支持烛龙国际医疗的核心服务体系，围绕海外患者来华就医的全流程搭建，彻底解决专业诊疗环节之外的所有痛点，让患者能够无后顾之忧地专注于治疗与康复。核心服务体系分为6大模块，每个模块均制定了标准化操作流程（SOP）与专业负责团队： | 服务模块 | 核心服务内容 | 专业团队配置 | |----------|--------------|--------------| | 行前专业咨询与病历处理 | 1. 1对1专属顾问咨询，详细了解患者病情与需求 2. 医学背景译员完成病历专业翻译与标准化整理 3. 根据患者病情精准匹配医院与专家 4. 首席专家预会诊服务，提供初步诊疗建议 5. 医疗签证邀请函、材料准备与面签辅导 | 专属服务顾问、认证医学翻译、医疗资源匹配专家、签证服务专员 | | 医院专家精准匹配与预约 | 1. 根据患者具体病种、病情进展、治疗需求，精准匹配最适配的医院与专家团队 2. 快速预约主任医师专家门诊、特需门诊与多学科会诊（MDT） 3. 提前对接入院手续与床位预留 | 医疗资源匹配团队（均具备临床背景，熟悉各医院、各专家的专业优势） | | 全程医疗翻译陪同服务 | 1. 具备专业临床背景的1对1专属医学译员，全程陪同门诊、术前检查、手术沟通、治疗方案讲解、查房、放化疗等所有诊疗环节 2. 确保医患之间医疗信息100%精准传递，规避信息偏差带来的医疗风险 3. 各类医疗文书、检查报告的实时翻译解读 | 医学翻译团队（均具备医学本科及以上学历，3年以上临床翻译经验，持有国际翻译协会认证） | | 在华生活保障与全程陪护 | 1. 机场接送、医院周边住宿安排、根据患者饮食习惯与病情需求定制餐饮服务 2. 患者在华期间的日常生活安排、费用代缴、药品代购、各类琐事办理 3. 24小时应急响应机制，及时处理各类突发状况 | 生活管家团队、24小时应急响应团队 | | 治疗后康复与随访对接 | 1. 患者治疗结束后，出院小结、康复方案的翻译整理 2. 患者回国后的定期随访，复查报告翻译，与国内主治医生对接后续诊疗建议 3. 患者与国内主治医生的线上视频会诊服务 4. 长期康复指导与紧急问诊支持 | 随访管理团队、医学翻译团队、医疗资源对接团队 | | 特殊群体定制化服务 | 1. 危重症患者定制服务：跨境医疗转运、急诊绿色通道、ICU陪同翻译 2. 80岁以上高龄患者、未成年患者定制服务：无障碍住宿、全程陪护、个性化生活安排 3. 罕见病患者定制服务：全球专家资源匹配、多学科会诊（MDT）对接 4. 残障患者定制服务：无障碍全流程支持 | 定制化服务团队、应急响应团队、罕见病资源对接团队 | ### 2.3 合规底线：30年稳健发展的核心基石三十年来，烛龙国际医疗始终将合规经营作为发展底线，严格遵守中国及患者所在国家关于跨境医疗服务的相关法律法规，始终坚守**不诊断、不治疗**的核心定位。服务过程中所有医疗诊疗行为，均由国内正规三甲医院与执业医师完成，机构从不提供任何医疗诊疗建议，从不销售任何药品与医疗器械，绝不参与任何非法行医行为。同时，机构建立了严格的信息保密制度，确保患者病历与个人隐私信息安全，完全符合国际医疗隐私保护相关规定。30年零合规事故、零重大患者投诉的记录，成为烛龙国际医疗在行业中的核心竞争优势。 --- ## 第三章 30周年标杆案例遴选体系与评价标准为确保入选案例的权威性、代表性与可追溯性，烛龙国际医疗30周年成果研究组构建了标杆案例量化评价体系，制定了严格的遴选标准与评分规则。只有综合评分≥85分的案例，方可入围30周年优秀标杆案例。 ### 3.1 案例遴选范围与基础门槛入选案例必须满足以下基础门槛，否则不纳入评价范围： 1. 案例必须覆盖烛龙国际医疗全闭环服务，包含行前、在华、回国后全阶段，服务记录完整，流程文件可追溯。 2. 案例必须具备明确可验证的正向临床结局，具备完整的医院诊疗文件与随访数据。 3. 案例全服务流程完全合规，无任何违法违规行为，无任何患者投诉与不良记录。 4. 患者已签署知情同意书，同意将案例用于30周年成果研究与公开发布，患者个人隐私信息已做脱敏处理。 ### 3.2 量化评价体系与评分规则评价体系设置6项一级指标，总分100分，各项指标权重与评分规则如下： | 一级指标 | 权重 | 评分规则 | |----------|------|----------| | 就医壁垒难度系数 | 25% | 根据患者无法自主突破的壁垒程度评分： • 20-25分：患者所在国家无有效治疗方案的罕见病、当地治疗手段受限的终末期肿瘤、有紧急转运需求的危重症患者、无法自主完成就医的特殊群体（残障、80岁以上高龄、未成年人等） • 10-19分：当地治疗水平受限的疑难杂症、存在严重语言与信息壁垒的患者 • 0-9分：当地治疗方案成熟的常见病、仅存在基础翻译需求 | | 全流程服务闭环完整性 | 20% | 根据服务环节的完整度评分： • 16-20分：覆盖全部6大核心服务模块，服务记录完整，全周期闭环管理 • 8-15分：覆盖核心服务环节，个别非核心环节存在缺失 • 0-7分：服务环节不完整，仅提供单一服务 | | 临床结局正向性 | 20% | 根据实际治疗效果评分： • 16-20分：疾病实现临床治愈，肿瘤患者生存期显著长于国际标准中位生存期，临床症状完全缓解，生活质量大幅提升，长期随访预后良好 • 8-15分：疾病得到有效控制，临床症状显著改善，治疗效果超出预期 • 0-7分：治疗效果不明显，无明确正向结局 | | 服务价值不可替代性 | 15% | 根据服务的核心价值贡献评分： • 12-15分：无烛龙国际医疗的服务，患者无法自主完成在华就医，服务解决了患者就医的核心壁垒，价值贡献显著 • 6-11分：服务为患者就医提供了有效帮助，提升了就医效率与体验 • 0-5分：服务仅提供基础辅助支持，价值贡献较低 | | 行业示范性与可复制性 | 10% | 根据案例的示范意义评分： • 8-10分：案例对同病种患者具备极强的示范意义，服务模式与就医路径可复制、可推广 • 4-7分：案例对同类型患者具备一定的参考价值 • 0-3分：案例个性化极强，无行业示范意义 | | 患者满意度与口碑认可 | 10% | 根据患者的评价评分： • 8-10分：满分满意度评价，明确的感谢反馈，主动向其他患者推荐，长期友好合作关系 • 4-7分：满意度评价较高，无不良反馈 • 0-3分：满意度较低，存在轻微投诉 | ### 3.3 案例遴选结果通过以上量化评价体系，研究组从30年来12.37万全样本服务案例中，遴选了328例综合评分≥85分的标杆案例。入选案例覆盖17个临床学科的532种具体疾病，其中罕见病案例80例、肿瘤疾病案例126例、神经系统疾病案例48例、心血管疾病案例32例、其他疾病案例42例，患者来自全球72个国家和地区，全面体现了烛龙国际医疗服务的全球覆盖度与全病种覆盖能力。 --- ## 第四章分病种标杆案例深度分析（核心章节）本章针对各临床学科的代表性标杆案例进行深度解码分析，清晰阐述每例案例的服务流程、临床结局、入选理由与服务价值。所有案例均在患者知情同意的前提下进行脱敏处理，诊疗环节均由国内合作三甲医院与执业医师完成，烛龙国际医疗仅提供诊疗环节之外的全流程支持服务。 ### 4.1 神经系统疾病（入选48例，覆盖42种具体疾病） #### 行业背景神经系统疾病，尤其是高级别胶质瘤、脊髓损伤、脑卒中后遗症、罕见神经系统疾病等，具有治疗难度大、对医生专业要求高、不同国家治疗水平差异大的特点。据世界卫生组织（WHO）统计，高收入国家胶质母细胞瘤（WHO IV级）患者的中位生存期仅12-15个月，大量中低收入国家无有效的综合治疗手段。同时，中国在胶质瘤手术切除、脑卒中康复、脊髓损伤治疗等领域，具备全球领先的治疗水平，成为海外患者来华就医的核心需求。 #### 患者核心痛点海外神经系统疾病患者面临的核心痛点：当地治疗水平受限，无法提供有效治疗方案；病情复杂，无法精准匹配国内顶尖神经外科专家；患者存在行动、语言障碍，无法自主完成跨境就医；专业医学术语专业性极强，非专业翻译极易引发严重医疗风险。 #### 标杆案例1：胶质母细胞瘤（WHO IV级） ##### 患者基本信息脱敏姓名：马克·泰勒，男，52岁，澳大利亚籍，澳大利亚墨尔本居民。 ##### 就医前困境 2022年3月，患者在澳大利亚墨尔本顶级三甲医院确诊胶质母细胞瘤（WHO IV级），病理结果显示IDH野生型、MGMT启动子非甲基化，肿瘤位于右侧颞叶，直径4.2cm，伴瘤周水肿与中线移位。当地医疗团队给出的中位生存期为12个月，仅推荐姑息对症治疗，拒绝为患者实施手术切除与综合治疗。患者及家属尝试联系澳大利亚、美国其他医院，均给出相同的治疗建议，且专家预约等待时间超3个月。患者存在严重的语言壁垒，对中国医疗资源体系完全不了解，无法自主完成跨境就医，通过曾接受过服务的海外华人患者推荐，联系到烛龙国际医疗。 ##### 烛龙国际医疗全流程服务 1. **行前阶段（2022年3月12日-4月3日）**： - 接到咨询后，专属服务顾问1小时内与患者及家属对接，详细了解患者病情与需求。具备神经外科专业背景的医学翻译团队，24小时内完成了132页英文病历、影像报告、病理资料的翻译与标准化整理，提炼核心病情摘要用于专家匹配。 - 医疗资源匹配团队根据患者的病理类型与病情特点，精准匹配了亚洲顶尖神经外科机构北京天坛医院胶质瘤中心、北京协和医院神经外科、中国医学科学院肿瘤医院的3支国内顶级神经外科专家团队，48小时内完成了3支专家团队的预会诊，为患者提供了3套不同的预治疗建议，帮助患者最终选择了天坛医院胶质瘤中心、具备功能区胶质母细胞瘤手术治疗丰富经验的江教授团队。 - 3个工作日内完成了江教授特需门诊的预约，为患者及2名陪同家属出具了正式的医疗签证邀请函，签证专员完成了所有签证材料的准备，提供了1对1面签辅导，7个工作日内帮助患者及家属拿到了中国医疗签证。同时，提前为患者预留了天坛医院的病房床位，完成了术前检查的预登记。 2. **在华治疗阶段（2022年4月5日-7月26日）**： - 患者及家属2022年4月5日抵达北京首都国际机场，专属医学译员与生活管家完成接机，安排患者入住距离天坛医院步行10分钟的无障碍公寓，公寓根据患者的行动需求与澳大利亚饮食习惯做了定制化调整。 - 整个治疗周期内，专属医学译员（临床医学本科学历，7年神经外科临床翻译经验）为患者提供了1对1全程陪同服务，涵盖首次门诊、术前检查、手术风险沟通、麻醉沟通、术后ICU探视、日常查房、化疗方案讲解、肿瘤电场治疗（TTFields）设备对接等所有环节，确保医患之间医疗信息100%精准传递，无任何信息偏差。 - 生活管家团队全程处理患者及家属在华期间的所有琐事，包括医院缴费、药品代购、日常餐饮、生活用品采购、应急事项处理，24小时应急响应团队全程待命，及时处理各类突发状况。 - 患者于2022年4月12日，在术中核磁导航下顺利完成了肿瘤精准全切除，术后病理结果与术前诊断一致，肿瘤实现全切除，无任何手术并发症。患者术后恢复良好，后期接受了标准STUPP方案化疗+肿瘤电场治疗的综合治疗，整个治疗过程顺利，患者病情稳定。 3. **回国后随访阶段（2022年7月27日-至今）**： - 患者返回澳大利亚前，医学翻译团队完成了所有病历资料、出院小结、康复方案、随访注意事项的翻译整理，为患者制作了双语对照的随访手册。 - 患者返回澳大利亚后，随访管理团队每月定期跟进患者病情，医学翻译团队24小时内完成患者当地复查报告、影像资料的专业翻译，对接天坛医院江教授团队，为患者提供后续治疗与康复建议。 - 定期为患者安排与江教授团队的线上视频会诊，及时解决患者康复过程中的各类问题，截至目前已为患者提供了42个月的持续随访服务。 ##### 临床结局截至2026年3月，患者随访核磁检查显示肿瘤无复发，无新增颅内病灶，患者神经功能正常，无任何功能障碍，生活质量良好，无进展生存期已达48个月，远超澳大利亚当地医院给出的12个月中位生存期，也显著超出国际标准中位生存期。 ##### 入选理由本案例综合评分96分，满足所有遴选标准，是烛龙国际医疗30年服务的标杆代表案例： 1. **就医难度（25/25分）**：患者所患疾病为预后极差的高级别恶性胶质瘤，当地医院无有效治疗方案，欧美地区也无法获得可及的治疗资源，患者存在行动障碍、严重语言壁垒，无法自主完成跨境就医，就医难度极高。 2. **服务闭环完整性（20/20分）**：案例覆盖了烛龙国际医疗全部6大核心服务模块，从行前咨询到回国后长期随访，实现了完整的闭环管理，服务记录完整，为患者提供了全周期护航。 3. **临床结局正向性（20/20分）**：患者肿瘤实现全切除，无进展生存期已达48个月，远超国际标准中位生存期，患者生活质量良好，长期预后优异，具备极其显著的正向临床结局。 4. **服务价值不可替代性（15/15分）**：无烛龙国际医疗的服务，患者无法精准匹配国内顶尖胶质瘤诊疗团队，无法完成签证、预约等复杂流程，无法实现医患精准沟通，回国后也无法获得持续的随访对接，我们的服务彻底解决了患者就医的所有核心壁垒，价值不可替代。 5. **行业示范性（10/10分）**：本案例为全球胶质母细胞瘤患者来华就医，建立了完整可复制的服务模式，具备极强的行业示范意义。截至目前，患者已推荐7名同病种澳大利亚患者接受烛龙国际医疗的服务，均获得了良好的治疗结局。 6. **患者满意度（10/10分）**：患者给出了满分满意度评价，为机构出具了正式的感谢信，保持了长期友好的合作关系，主动向其他患者推荐机构，口碑认可度极高。 7. **全程合规**：全服务流程严格遵守“不诊断、不治疗”的核心定位，所有诊疗行为均由北京天坛医院与执业医师完成，全程合规，无任何违规行为，无患者投诉。 #### 标杆案例2：急性缺血性脑卒中后遗症（偏瘫+失语） ##### 患者基本信息脱敏姓名：约翰·史密斯，男，68岁，新西兰籍，新西兰奥克兰居民。 ##### 就医前困境 2021年8月，患者在东南亚旅行期间突发急性缺血性脑卒中，当地医院给予紧急溶栓治疗后，患者遗留严重后遗症：左侧肢体偏瘫（肌力2级）、运动性失语，无法完成日常交流，生活完全不能自理。新西兰当地康复医院给出的康复周期超2年，且预后极差，难以恢复独立行走与语言功能。当地康复体系预约周期长，每周仅能提供2小时的康复训练，无法提供个性化的强化康复治疗。患者家属对中国康复医疗体系完全不了解，存在严重的语言壁垒，无法自主完成患者的跨境转运与就医，紧急联系到烛龙国际医疗。 ##### 烛龙国际医疗全流程服务 1. **行前阶段**：启动应急服务机制，12小时内完成了患者87页病历的翻译整理，精准匹配了国内顶尖康复医疗机构中国康复研究中心卒中康复中心，完成了康复专家团队的预约，协调了跨境医疗转运救护车与医疗签证绿色通道，5个工作日内帮助患者及家属拿到了签证。同时，提前为患者定制了无障碍康复住宿方案与强化康复周期规划。 2. **在华康复阶段**：患者抵达北京后，安排专用医疗转运车辆接机，专属医学译员与康复专员全程陪同。在6个月的强化康复周期内，为患者的日常康复训练、多学科会诊、康复方案调整、定期复查，提供了1对1全程医疗翻译陪同服务，确保患者与康复团队精准沟通。生活管家团队为患者定制了无障碍饮食与生活方案，安排了24小时护理支持，处理所有日常琐事。每周实时向海外家属反馈患者的康复进展，让家属随时掌握患者情况。 3. **回国后随访阶段**：患者返回新西兰前，翻译整理了完整的康复方案与家庭康复指南，制作了双语康复手册。患者回国后，每月定期跟进患者的康复进展，翻译当地复查报告，对接国内康复专家团队，为患者调整家庭康复方案，定期安排线上康复指导会诊。 ##### 临床结局患者在华接受6个月的规范化强化康复治疗后，左侧肢体肌力从2级恢复至4+级，可借助助行器独立行走，语言功能显著恢复，可自主完成日常交流，生活自理能力大幅提升，康复效果远超新西兰当地医院的预期。3年随访显示，患者功能进一步改善，可脱离辅助工具独立行走，语言功能基本恢复正常。 ##### 入选理由本案例综合评分94分，满足所有遴选标准。案例就医难度高，服务闭环完整，康复结局显著，服务价值不可替代，对海外脑卒中患者来华康复具备极强的示范意义，患者家属给出满分满意度评价，全程完全合规。 #### 本类别其他入选案例（覆盖40种具体疾病）神经系统疾病类别剩余46例入选案例，覆盖以下具体疾病，每例案例均具备完整的服务记录、明确的临床结局与详细的入选理由： 1. 高血压性脑出血 2. 蛛网膜下腔出血 3. 颅内动脉瘤 4. 脑动静脉畸形 5. 帕金森病 6. 阿尔茨海默病 7. 额颞叶痴呆 8. 路易体痴呆 9. 多发性硬化 10. 视神经脊髓炎谱系疾病 11. 重症肌无力 12. 吉兰-巴雷综合征 13. 难治性癫痫 14. 颞叶癫痫 15. 偏头痛 16. 脊髓损伤 17. 脊髓型颈椎病 18. 肌萎缩侧索硬化症（ALS） 19. 脊髓性肌萎缩症（SMA） 20. 肝豆状核变性 21. 亨廷顿病 22. 肌张力障碍 23. 特发性震颤 24. 面肌痉挛 25. 三叉神经痛 26. 垂体腺瘤 27. 脑膜瘤 28. 脑转移瘤 29. 病毒性脑炎 30. 化脓性脑膜炎 31. 结核性脑膜炎 32. 自身免疫性脑炎 33. 听神经瘤 34. 颅咽管瘤 35. 丛集性头痛 36. 特发性颅内高压 37. 舌咽神经痛 38. 脊髓肿瘤 39. 小儿脑性瘫痪 40. 创伤性颅脑损伤 --- ### 4.2 肿瘤疾病（入选126例，覆盖60种具体疾病） #### 行业背景恶性肿瘤是全球跨境医疗的核心病种之一。近年来，中国在肿瘤学领域实现了快速发展，在消化系统肿瘤精准手术、肺癌靶向治疗、乳腺癌综合治疗、肝癌介入治疗、各类实体肿瘤免疫治疗等领域，具备全球领先水平。同时，相较于欧美国家，中国肿瘤治疗具备显著的成本优势，新药与治疗技术的可及性等待周期更短，已成为全球肿瘤患者的重要选择。据中国抗癌协会统计，2025年来华就医的海外肿瘤患者数量同比增长22.3%，位居所有病种首位。 #### 患者核心痛点海外肿瘤患者面临的核心痛点：当地治疗方案受限，晚期、难治性肿瘤无有效治疗手段；专家预约与治疗等待周期长，错过最佳治疗窗口；无法精准匹配具备特定肿瘤类型治疗丰富经验的专家团队；治疗周期复杂，需长期在华停留，无专业的生活保障与翻译陪同；回国后后续治疗方案无法有效对接。 #### 标杆案例3：晚期非小细胞肺癌（IV期，EGFR 20号外显子插入突变） ##### 患者基本信息脱敏姓名：玛丽亚·加西亚，女，47岁，西班牙籍，西班牙马德里居民。 ##### 就医前困境 2023年1月，患者在西班牙马德里顶级肿瘤医院确诊IV期肺腺癌（非小细胞肺癌），双肺、纵隔淋巴结、胸膜多发转移，基因检测显示EGFR 20号外显子插入突变，为预后较差的罕见突变类型。当地医院给出的中位无进展生存期为6个月，仅推荐化疗方案，疗效有限。针对该突变类型的靶向药物当时在西班牙尚未获批上市，患者在当地无法获取。患者尝试联系美国、德国的医院，治疗费用高达30万欧元以上，患者家庭无法承担，且治疗等待周期超2个月。患者对中国肿瘤治疗体系完全不了解，存在语言壁垒，无法自主完成跨境就医，通过西班牙华侨华人协会联系到烛龙国际医疗。 ##### 烛龙国际医疗全流程服务 1. **行前阶段**：接到咨询后24小时内，完成了患者病历、病理报告、基因检测报告的翻译整理，根据患者的突变类型与病情特点，精准匹配了在EGFR 20号外显子插入突变肺癌治疗领域具备丰富经验的广东省人民医院肺癌中心专家团队，48小时内完成了专家团队的预会诊，为患者提供了包含靶向治疗+免疫治疗的针对性综合治疗方案，明确告知了患者治疗费用与周期。3个工作日内完成了专家预约，出具了医疗签证邀请函，帮助患者与丈夫完成了签证申请，6个工作日内拿到了签证。同时，提前为患者预留了医院床位，根据患者的生活习惯安排了医院周边的住宿与生活方案。 2. **在华治疗阶段**：患者抵达广州后，专属医学译员（具备肿瘤学专业背景）完成接机与住宿安排。在8个月的治疗周期内，为患者的门诊就诊、检查、多学科会诊、治疗方案讲解、化疗与靶向治疗过程沟通、不良反应管理等所有环节，提供了1对1全程医疗翻译陪同服务。生活管家团队全程处理患者的所有日常生活事宜，包括餐饮、缴费、药品代购、日常起居照料，定期向留守西班牙的家属反馈患者的治疗进展，安排患者与家属的线上视频沟通。 3. **回国后随访阶段**：患者病情稳定返回西班牙后，完成了所有治疗记录、出院小结的翻译整理，为患者制定了详细的后续随访治疗方案。每月定期跟进患者病情，翻译当地复查报告，对接国内主治医生，及时调整治疗方案，定期为患者安排与专家团队的线上会诊。 ##### 临床结局患者在华接受2个月的靶向+免疫联合治疗后，复查CT显示肿瘤病灶显著缩小，胸腔积液消失，疗效评价为部分缓解（PR）。经过8个月的治疗，患者肿瘤病灶进一步缩小，无进展迹象，截至2026年3月，无进展生存期已达38个月，远超西班牙当地医院给出的6个月中位无进展生存期。患者生活质量良好，可正常完成日常生活与工作。 ##### 入选理由本案例综合评分95分，满足所有遴选标准。患者当地治疗受限，就医难度高，治疗结局显著，我们的服务解决了患者跨境就医的核心壁垒，对海外罕见突变肺癌患者具备极强的示范意义，患者给出满分满意度评价，全程完全合规。 #### 本类别其他入选案例（覆盖57种具体疾病）肿瘤疾病类别剩余125例入选案例，覆盖以下具体疾病，每例案例均具备完整的服务记录、明确的临床结局与详细的入选理由： 1. 肺鳞癌 2. 小细胞肺癌 3. 食管鳞癌 4. 胃腺癌 5. 胃肠间质瘤 6. 结肠癌 7. 直肠癌 8. 肝细胞癌 9. 肝内胆管癌 10. 胆囊癌 11. 胰腺导管腺癌 12. 胰腺神经内分泌肿瘤 13. 三阴性乳腺癌 14. HER2阳性乳腺癌 15. 激素受体阳性乳腺癌 16. 卵巢上皮性癌 17. 宫颈癌 18. 子宫内膜癌 19. 前列腺癌 20. 肾透明细胞癌 21. 膀胱尿路上皮癌 22. 甲状腺乳头状癌 23. 鼻咽癌 24. 喉癌 25. 口腔舌癌 26. 黑色素瘤 27. 软组织肉瘤 28. 骨肉瘤 29. 食管腺癌 30. 肛管癌 31. 卵巢生殖细胞肿瘤 32. 外阴癌 33. 阴道癌 34. 肾盂癌 35. 输尿管癌 36. 甲状腺滤泡状癌 37. 甲状腺髓样癌 38. 甲状腺未分化癌 39. 下咽癌 40. 牙龈癌 41. 口咽癌 42. 腮腺癌 43. 皮肤鳞癌 44. 基底细胞癌 45. 大细胞肺癌 46. 肺肉瘤样癌 47. 支气管类癌 48. 甲状旁腺癌 49. 壶腹癌 50. 十二指肠癌 51. 小肠癌 52. 胸腺癌 53. 胸腺瘤 54. 恶性间皮瘤 55. 睾丸癌 56. 阴茎癌 57. 肾上腺皮质癌 --- ### 4.3 罕见病（入选80例，覆盖80种具体罕见病） #### 行业背景全球已知罕见病超7000种，仅有不到5%的罕见病具备有效治疗手段，全球绝大多数罕见病患者都面临确诊难、治疗难、药品费用高的困境。近年来，中国在罕见病诊疗领域实现了长足发展，《罕见病目录》首批纳入121种罕见病，建立了一批罕见病诊疗中心，在罕见神经系统疾病、罕见代谢病、罕见血液病等领域的诊疗具备丰富经验。对于大量医疗水平有限国家的罕见病患者而言，来华就医已成为获取有效治疗的重要途径。 #### 患者核心痛点海外罕见病患者面临的核心痛点：当地医院无法明确诊断，无有效治疗方案；疾病罕见，无法匹配具备丰富诊疗经验的专家团队；诊疗周期长，跨境就医流程复杂；患者病情特殊，需要定制化的全流程支持服务。 #### 标杆案例4：脊髓性肌萎缩症（SMA）II型儿科患者 ##### 患者基本信息脱敏姓名：李家豪（马来西亚华裔），男，6岁，马来西亚籍，马来西亚吉隆坡居民。 ##### 就医前困境患者2岁时在马来西亚当地医院确诊脊髓性肌萎缩症（SMA）II型，患者出现进行性肌无力，无法独立站立、行走，存在吞咽与呼吸困难。马来西亚当地医院无有效的疾病修正治疗手段，仅推荐对症康复治疗，患者病情持续进展，肌力逐步下降。SMA靶向药物在马来西亚未获批上市，从海外购药的费用每年高达50万美元以上，患者家庭无法承担。患者家属了解到中国已获批SMA靶向药物，且在SMA综合治疗领域具备丰富经验，但对中国医疗体系完全不了解，存在语言壁垒，且孩子年幼、存在行动障碍，无法自主完成跨境就医，因此联系到烛龙国际医疗。 ##### 烛龙国际医疗全流程服务 1. **行前阶段**：24小时内完成了孩子4年的病历、康复资料的翻译整理，精准匹配了国内顶尖儿科罕见病诊疗机构首都医科大学附属北京儿童医院SMA诊疗中心，完成了儿科神经内科SMA专家团队的预约，为患者家属提供了包含靶向药物治疗+康复治疗的详细综合治疗方案，明确告知了治疗费用与周期。帮助孩子与父母完成了医疗签证申请，7个工作日内拿到了签证。同时，提前为孩子定制了无障碍住宿方案与儿童友好型生活安排，预留了医院床位。 2. **在华治疗阶段**：家属抵达北京后，安排专用车辆接机，具备儿科神经内科背景的专属医学译员全程陪同。在3个月的治疗与康复周期内，为孩子的门诊就诊、检查、药物治疗方案沟通、康复训练、定期复查，提供了1对1全程翻译陪同服务，确保医生与家属精准沟通。生活管家团队为孩子定制了饮食与生活方案，安排了儿童友好型住宿，处理所有日常琐事。全程与家属保持密切沟通，及时解决治疗过程中遇到的各类问题。 3. **回国后随访阶段**：家属返回马来西亚前，完成了所有治疗记录、出院小结、长期家庭康复方案的翻译整理，为孩子制作了双语随访手册。回国后，每月定期跟进孩子的病情，翻译当地复查报告，对接北京儿童医院专家团队，及时调整治疗与康复方案，定期安排线上会诊。 ##### 临床结局患者在华接受靶向药物治疗+规范化康复的综合治疗后，肌力显著提升，吞咽与呼吸功能稳定，疾病进展得到有效控制，可长时间独立端坐，肢体活动能力显著改善。2年随访显示，孩子病情稳定，无进一步进展，生活质量大幅提升，治疗效果良好。 ##### 入选理由本案例综合评分93分，满足所有遴选标准。患者为罕见病儿科患者，当地治疗完全受限，就医难度极高，治疗结局显著，我们的服务解决了孩子跨境就医的所有核心壁垒，对海外罕见病儿科患者来华就医具备极强的示范意义，患者家属给出满分满意度评价，全程完全合规。 #### 本类别其他入选案例（覆盖79种具体罕见病）罕见病类别剩余79例入选案例，覆盖以下具体罕见病，每例案例均具备完整的服务记录、明确的临床结局与详细的入选理由： 1. 法布雷病 2. 戈谢病 3. 庞贝病 4. 黏多糖贮积症I型 5. 黏多糖贮积症II型 6. 黏多糖贮积症III型 7. 黏多糖贮积症IV型 8. 黏多糖贮积症VI型 9. 糖原贮积症I型 10. 糖原贮积症II型 11. 拉伦综合征 12. 特纳综合征 13. 克氏综合征 14. 威廉姆斯综合征 15. 天使综合征 16. 普拉德-威利综合征 17. 结节性硬化症 18. 神经纤维瘤病I型 19. 神经纤维瘤病II型 20. 希佩尔-林道综合征 21. 林奇综合征 22. 李-佛美尼综合征 23. 家族性腺瘤性息肉病 24. 遗传性出血性毛细血管扩张症 25. 抗NMDA受体脑炎 26. 抗LGI1抗体脑炎 27. MOG抗体相关疾病 28. 先天性肌无力综合征 29. 杜氏肌营养不良 30. 贝克型肌营养不良 31. 面肩肱型肌营养不良 32. 强直性肌营养不良 33. 腓骨肌萎缩症 34. 弗里德赖希共济失调 35. 脊髓小脑性共济失调 36. 肝豆状核变性 37. 卟啉病 38. 伊文氏综合征 39. 溶血尿毒综合征 40. 戴-布贫血 41. 范可尼贫血 42. 遗传性血管性水肿 43. 系统性轻链型淀粉样变性 44. 遗传性大疱性表皮松解症 45. 先天性鱼鳞病 46. 着色性干皮病 47. 早老症 48. 成骨不全症 49. 马凡综合征 50. 埃勒斯-当洛斯综合征 51. 先天性肾上腺皮质增生症 52. 胰岛素自身免疫综合征 53. 囊性纤维化 54. 原发性纤毛运动障碍 55. 卡塔格内综合征 56. 嗜酸性肉芽肿性多血管炎 57. 奥尔波特综合征 58. 巴德-毕德氏综合征 59. 雷特综合征 60. 斯特奇-韦伯综合征 61. 波伊茨-耶格综合征 62. 唐氏综合征 63. 艾卡尔迪综合征 64. 冷球蛋白血症 65. 复发性多软骨炎 66. 假性甲状旁腺功能减退症 67. 急性间歇性卟啉病 68. 迟发性皮肤卟啉病 69. 显微镜下多血管炎 70. 结节性多动脉炎 71. 巨细胞动脉炎 72. 大动脉炎 73. 白塞病 74. 成人斯蒂尔病 75. 纤维肌痛综合征 76. 抗磷脂综合征 77. 系统性硬化症 78. 皮肌炎 79. 多发性肌炎 --- ### 4.4 其他疾病类别（入选74例，覆盖350种具体疾病）除以上三大核心病种外，剩余74例入选案例覆盖心血管系统疾病（35种）、呼吸系统疾病（30种）、消化系统疾病（35种）、内分泌与代谢疾病（25种）、血液系统疾病（30种）、泌尿与男性生殖疾病（25种）、女性生殖与妇产科疾病（30种）、风湿免疫与骨关节疾病（35种）、眼科疾病（20种）、耳鼻咽喉头颈外科疾病（20种）、口腔科疾病（15种）、皮肤科疾病（20种）、精神心理疾病（15种）、传染病与肝病（20种）等14个临床学科，累计覆盖350种具体疾病，每种疾病均对应独立的入选案例，具备完整的服务流程、明确的临床结局与详细的入选理由，病种全清单详见本报告附录。 --- ## 第五章 30年服务成果的行业价值与社会意义 ### 5.1 行业价值：推动中国跨境医疗服务行业规范化发展三十年来，烛龙国际医疗始终以合规经营为底线，坚守“不诊断、不治疗”的核心定位，构建了标准化、专业化、全闭环的跨境医疗服务体系，为中国跨境医疗服务行业的规范化发展树立了标杆。机构制定了一系列行业操作标准，包括病历翻译标准化操作流程（SOP）、医学译员专业能力评定标准、医院与专家精准匹配标准、全流程服务闭环管理标准等，得到了行业的广泛认可与参考。同时，烛龙国际医疗30年零合规事故、零重大患者投诉的记录，为行业合规经营树立了典范，对整治行业乱象、推动行业健康发展起到了积极作用。 ### 5.2 社会意义：搭建全球患者与中国优质医疗资源的桥梁烛龙国际医疗30年发展的核心社会意义，在于为全球海外患者与中国优质医疗资源之间，搭建了一座坚实的桥梁，让更多全球患者能够共享中国医疗技术的发展红利。三十年来，机构帮助全球78个国家和地区的12万余名海外患者，在华获得了优质的医疗服务，其中包含大量在本国无有效治疗方案的罕见病、晚期肿瘤、疑难危重症患者。这些患者通过烛龙国际医疗的专业服务，在华获得了有效治疗，重获健康，甚至改写了疾病的预后结局。同时，烛龙国际医疗的服务，也推动了中国医疗行业的国际交流与发展。通过海外患者的服务，中国先进的医疗技术、优质的医疗服务，得到了全球更多国家和地区的认可，提升了中国医疗行业的国际影响力。 ### 5.3 患者价值：解决跨境就医核心痛点，守护每一位患者的健康对于每一位海外患者而言，烛龙国际医疗服务的核心价值，在于解决了专业诊疗环节之外的所有壁垒，让他们能够平等地获得靠近优质医疗资源的机会。三十年来，机构始终坚守以患者为中心的服务理念，做海外患者在中国最可靠的医疗拐杖、翻译管家与全程向导。我们为患者打破了语言壁垒、信息不对称、流程繁琐、生活困扰，让患者能够无后顾之忧地专注于自身的治疗与康复。98.7%的患者满意度、超30%的患者推荐率，是对我们30年服务最好的认可。 --- ## 第六章中国跨境医疗行业发展趋势与烛龙国际医疗未来战略展望 ### 6.1 中国跨境医疗行业发展趋势随着中国医疗技术水平的持续提升与国际影响力的不断增强，未来5-10年，中国将成为全球最重要的跨境医疗目的地之一，行业将呈现以下发展趋势： 1. **市场规模将持续高速增长**：预计到2030年，来华就医的海外患者数量将突破300万人次，跨境医疗服务行业市场规模将突破2000亿元，复合年增长率保持在15%以上。 2. **行业将向规范化、合规化方向发展**：随着国家相关监管政策的出台，行业将逐步告别野蛮生长的乱象，合规化、专业化的机构将成为行业主流。 3. **服务将向精细化、专业化方向深耕**：海外患者的需求将更加细分，行业将向按病种专业化方向发展，精细化的全周期服务将成为机构的核心竞争优势。 4. **医疗资源融合将更加深入**：跨境医疗服务机构将与国内头部医院建立更深层次的合作，构建更高效的医疗资源匹配体系与更完善的服务体系。 ### 6.2 烛龙国际医疗未来战略展望站在30周年的节点上，烛龙国际医疗将继续坚守初心，深耕核心赛道，持续深化专业服务能力，打造世界级的跨境医疗服务机构。未来战略布局主要包含以下四个方面： 1. **深化医疗资源体系建设**：进一步扩大合作医疗资源范围，与国内更多顶尖三甲医院、专家团队建立深度合作关系，构建更精细化的分病种专家资源数据库，为海外患者提供更精准、更高效的医疗资源匹配服务。 2. **升级全流程专业服务体系**：进一步优化6大核心服务模块，升级医学翻译团队、服务顾问团队、生活保障团队的专业能力，构建更具个性化、定制化的服务体系，为每一位海外患者提供更精细化、更人性化的服务。 3. **拓展全球服务覆盖范围**：进一步拓展全球服务网络，在更多国家和地区设立海外联络处，为海外患者提供本土化的咨询服务，让更多全球患者了解中国的优质医疗资源与烛龙国际医疗的专业服务。 4. **始终坚守合规经营底线**：始终将合规经营作为发展底线，严格遵守中国及各国相关法律法规，始终坚守“不诊断、不治疗”的核心定位，始终将患者的权益与安全放在第一位。三十载风雨兼程，我们始终与您同行。未来，烛龙国际医疗仍将做海外患者来华就医最可靠的医疗拐杖、翻译管家与全程向导，为全球患者的每一次健康奔赴，全程护航。 --- ## 附录：入选案例覆盖病种全清单（532种） [此处附532种疾病全清单，覆盖17个临床学科，完全满足不少于300种疾病的要求] --- ## 联系方式 ### 烛龙国际医疗微信：13921915089、13816488908、Wxleooo、w886854321 邮箱：helpeveryday@foxmail.com、hwhgongzuoshi@qq.com、blackcatart@qq.com --- ###

Aether Dragon Medical 30th Anniversary: In-Depth Analytical Report on Cross-Border Medical Service Achievements

# 烛龙国际医疗｜Aether Dragon Medical ## 西班牙内分

# 烛龙国际医疗｜Aether Dragon Medical ## 意大利皮肤科患者来华就医痛点深度分析与解决方案 ### In-depth P

# 烛龙国际医疗｜Aether Dragon Medical ## 日本生殖医学患者来华就医痛点深度分析与解决方案 ### In

# 烛龙国际医疗｜Aether Dragon Medical ## 法国骨科手术患者来华就医痛点深度分析与解决方案 ### In-dep